Supporting the therapeutic targeting of OS: Studies have demonstrated that activation of the Nrf2/ARE pathway alleviates prostatic hyperplasia in BPH rat models by suppressing OS (96). This evidence concerns the gene NFE2L2 and benign prostatic hyperplasia.